Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Use of Molecular Modeling to Design Selective NTS2 Neurotensin Analogues.

Fanelli R, Floquet N, Besserer-Offroy É, Delort B, Vivancos M, Longpré JM, Renault P, Martinez J, Sarret P, Cavelier F.

J Med Chem. 2017 Apr 27;60(8):3303-3313. doi: 10.1021/acs.jmedchem.6b01848. Epub 2017 Apr 10.

PMID:
28368584
2.

The signaling signature of the neurotensin type 1 receptor with endogenous ligands.

Besserer-Offroy É, Brouillette RL, Lavenus S, Froehlich U, Brumwell A, Murza A, Longpré JM, Marsault É, Grandbois M, Sarret P, Leduc R.

Eur J Pharmacol. 2017 Jun 15;805:1-13. doi: 10.1016/j.ejphar.2017.03.046. Epub 2017 Mar 22.

PMID:
28341345
3.

Structure-activity relationship of novel macrocyclic biased apelin receptor agonists.

Murza A, Sainsily X, Côté J, Bruneau-Cossette L, Besserer-Offroy É, Longpré JM, Leduc R, Dumaine R, Lesur O, Auger-Messier M, Sarret P, Marsault É.

Org Biomol Chem. 2017 Jan 4;15(2):449-458. doi: 10.1039/c6ob02247b.

PMID:
27924341
4.

Design, synthesis, and biological evaluation of CXCR4 ligands.

Mona CE, Besserer-Offroy É, Cabana J, Leduc R, Lavigne P, Heveker N, Marsault É, Escher E.

Org Biomol Chem. 2016 Nov 2;14(43):10298-10311.

PMID:
27752700
5.

Structure-Activity Relationship and Signaling of New Chimeric CXCR4 Agonists.

Mona CE, Besserer-Offroy É, Cabana J, Lefrançois M, Boulais PE, Lefebvre MR, Leduc R, Lavigne P, Heveker N, Marsault É, Escher E.

J Med Chem. 2016 Aug 25;59(16):7512-24. doi: 10.1021/acs.jmedchem.6b00566. Epub 2016 Aug 11.

PMID:
27434274
6.

Identification of 2-({[1-(4-Fluorophenyl)-5-(2-methoxyphenyl)-1H-pyrazol-3-yl]carbonyl}amino)tricyclo[3.3.1.13,7]decane-2-carboxylic Acid (NTRC-844) as a Selective Antagonist for the Rat Neurotensin Receptor Type 2.

Thomas JB, Vivancos M, Giddings AM, Wiethe RW, Warner KR, Murza A, Besserer-Offroy É, Longpré JM, Runyon SP, Decker AM, Gilmour BP, Sarret P.

ACS Chem Neurosci. 2016 Sep 21;7(9):1225-31. doi: 10.1021/acschemneuro.6b00097. Epub 2016 Jul 13.

PMID:
27359371
7.

Discovery and Structure-Activity Relationship of a Bioactive Fragment of ELABELA that Modulates Vascular and Cardiac Functions.

Murza A, Sainsily X, Coquerel D, Côté J, Marx P, Besserer-Offroy É, Longpré JM, Lainé J, Reversade B, Salvail D, Leduc R, Dumaine R, Lesur O, Auger-Messier M, Sarret P, Marsault É.

J Med Chem. 2016 Apr 14;59(7):2962-72. doi: 10.1021/acs.jmedchem.5b01549. Epub 2016 Mar 30.

PMID:
26986036
8.

Synthesis and Characterization in Vitro and in Vivo of (l)-(Trimethylsilyl)alanine Containing Neurotensin Analogues.

Fanelli R, Besserer-Offroy É, René A, Côté J, Tétreault P, Collerette-Tremblay J, Longpré JM, Leduc R, Martinez J, Sarret P, Cavelier F.

J Med Chem. 2015 Oct 8;58(19):7785-95. doi: 10.1021/acs.jmedchem.5b00841. Epub 2015 Sep 16.

PMID:
26348111
9.

C-Terminal modifications of apelin-13 significantly change ligand binding, receptor signaling, and hypotensive action.

Murza A, Besserer-Offroy É, Côté J, Bérubé P, Longpré JM, Dumaine R, Lesur O, Auger-Messier M, Leduc R, Sarret P, Marsault É.

J Med Chem. 2015 Mar 12;58(5):2431-40. doi: 10.1021/jm501916k. Epub 2015 Feb 24.

PMID:
25668242
10.

Conjugation of a brain-penetrant peptide with neurotensin provides antinociceptive properties.

Demeule M, Beaudet N, Régina A, Besserer-Offroy É, Murza A, Tétreault P, Belleville K, Ché C, Larocque A, Thiot C, Béliveau R, Longpré JM, Marsault É, Leduc R, Lachowicz JE, Gonias SL, Castaigne JP, Sarret P.

J Clin Invest. 2014 Mar;124(3):1199-213. doi: 10.1172/JCI70647. Epub 2014 Feb 17.

11.

Elucidation of the structure-activity relationships of apelin: influence of unnatural amino acids on binding, signaling, and plasma stability.

Murza A, Parent A, Besserer-Offroy E, Tremblay H, Karadereye F, Beaudet N, Leduc R, Sarret P, Marsault É.

ChemMedChem. 2012 Feb 6;7(2):318-25. doi: 10.1002/cmdc.201100492. Epub 2011 Dec 13.

PMID:
22170700

Supplemental Content

Loading ...
Support Center